THE STUDY highlighted in this issue of the ARCHIVES1 indicates yet again the great potential value of cutaneous sunscreen application, when undertaken conscientiously and carefully, against the now extremely well-documented ravages of sunlight in both the short and long term. This splendid randomized controlled trial is the continuation of a previous one showing sunscreen efficacy against the development of squamous cell carcinoma.2 It provides further evidence in a very large number of adults (1621 subjects aged 25-74 years), over a reasonably long time (2½ years), in a very ultraviolet (UV)-intense environment (Queensland, Australia), that frequent, liberal applications of high-protection sunscreen by ordinary people under normal circumstances is 25% more efficient against the development of potentially premalignant actinic keratoses than ad hoc applications. Less difference was seen over the subsequent and final 2 years of the study, arguably because of increased care in applying sunscreen regularly in the control group as the trial progressed. This is a great relief to us dermatologists because it proves that we are not advising our patients incorrectly; but it also clearly shows that participants in the control arm of the trial, who were using sunscreens just as most of us do, did not fare as well as their counterparts in the study group. So why not? Well, because sunscreens should be used in the context discussed below.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.